To test if pharmacological suppression of mTOR signaling will suppress the growth of endometrial cancer, we treated cells of an endometrial line, Ishikawa, with two FDA-approved mTOR inhibitors (Everolimus and BEZ235). The gene discussed is MTOR; the disease is endometrial cancer.